Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy

© 2016 International Medical Press. Background: Antiretroviral (ARV) regimens used for the prevention of mother-to-child transmission of HIV have evolved over time. We evaluated the contribution of different ARV regimens on the reduction of the plasma HIV RNA viral load (VL) during pregnancy. Method...

Full description

Saved in:
Bibliographic Details
Main Authors: Patumrat Sripan, Sophie Le Coeur, Lily Ingsrisawang, Tim R. Cressey, Naïm Bouazza, Frantz Foissac, Nicole Ngo-Giang-Huong, Patrinee Traisathit, Ussanee Srirompotong, Orada Patamasingh Na Ayudhaya, Achara Puangsombat, Jantana Jungpipun, Kanokwan Jittayanun, Jean Marc Tréluyer, Gonzague Jourdain, Marc Lallemant, Saïk Urien
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84991493939&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/56248
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-56248
record_format dspace
spelling th-cmuir.6653943832-562482018-09-05T03:12:45Z Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy Patumrat Sripan Sophie Le Coeur Lily Ingsrisawang Tim R. Cressey Naïm Bouazza Frantz Foissac Nicole Ngo-Giang-Huong Patrinee Traisathit Ussanee Srirompotong Orada Patamasingh Na Ayudhaya Achara Puangsombat Jantana Jungpipun Kanokwan Jittayanun Jean Marc Tréluyer Gonzague Jourdain Marc Lallemant Saïk Urien Medicine Pharmacology, Toxicology and Pharmaceutics © 2016 International Medical Press. Background: Antiretroviral (ARV) regimens used for the prevention of mother-to-child transmission of HIV have evolved over time. We evaluated the contribution of different ARV regimens on the reduction of the plasma HIV RNA viral load (VL) during pregnancy. Methods: A total of 1,833 VL measurements from ARVnaive pregnant women participating in perinatal prevention trials in Thailand were included. Women received either zidovudine (ZDV) monotherapy, ZDV plus lopinavir/ ritonavir (LPV/r), or ZDV plus lamivudine (3TC) plus LPV/r. VL time-course during pregnancy was described as a function of pretreatment VL and treatment duration using an Emax non-linear mixed-effect model. VL reduction and median time to achieve a VL<50 copies/ml were estimated for each regimen. Results: Among 745 women, 279 (37%), 145 (20%) and 321 (43%) received ZDV monotherapy, ZDV+LPV/r and ZDV+3TC+LPV/r, respectively. The predicted VL reduction from baseline to delivery after a median of 10 weeks of treatment were 0.5, 2.7 and 2.9 log10 copies/ml with ZDV monotherapy, ZDV+LPV/r and ZDV+3TC+LPV/r, respectively. At delivery, 1%, 57% and 63% of women receiving ZDV monotherapy, ZDV+LPV/r or ZDV+3TC+LPV/r had a VL<50 copies/ml. The addition of 3TC to ZDV+LPV/r reduced the time to achieve a VL<50 copies/ml and the higher the pretreatment VL, the larger the effect 3TC had on reducing the time to VL<50 copies/ml. Conclusions: The addition of 3TC to ZDV+LPV/r was associated with a slight further VL reduction but the time to reach a VL<50 copies/ml was shorter. This beneicial effect of 3TC is crucial for prevention of motherto-child transmission in women who receive ARVs late and with high pretreatment VL. 2018-09-05T03:11:25Z 2018-09-05T03:11:25Z 2016-01-01 Journal 20402058 13596535 2-s2.0-84991493939 10.3851/IMP3001 https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84991493939&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/56248
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
Pharmacology, Toxicology and Pharmaceutics
spellingShingle Medicine
Pharmacology, Toxicology and Pharmaceutics
Patumrat Sripan
Sophie Le Coeur
Lily Ingsrisawang
Tim R. Cressey
Naïm Bouazza
Frantz Foissac
Nicole Ngo-Giang-Huong
Patrinee Traisathit
Ussanee Srirompotong
Orada Patamasingh Na Ayudhaya
Achara Puangsombat
Jantana Jungpipun
Kanokwan Jittayanun
Jean Marc Tréluyer
Gonzague Jourdain
Marc Lallemant
Saïk Urien
Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy
description © 2016 International Medical Press. Background: Antiretroviral (ARV) regimens used for the prevention of mother-to-child transmission of HIV have evolved over time. We evaluated the contribution of different ARV regimens on the reduction of the plasma HIV RNA viral load (VL) during pregnancy. Methods: A total of 1,833 VL measurements from ARVnaive pregnant women participating in perinatal prevention trials in Thailand were included. Women received either zidovudine (ZDV) monotherapy, ZDV plus lopinavir/ ritonavir (LPV/r), or ZDV plus lamivudine (3TC) plus LPV/r. VL time-course during pregnancy was described as a function of pretreatment VL and treatment duration using an Emax non-linear mixed-effect model. VL reduction and median time to achieve a VL<50 copies/ml were estimated for each regimen. Results: Among 745 women, 279 (37%), 145 (20%) and 321 (43%) received ZDV monotherapy, ZDV+LPV/r and ZDV+3TC+LPV/r, respectively. The predicted VL reduction from baseline to delivery after a median of 10 weeks of treatment were 0.5, 2.7 and 2.9 log10 copies/ml with ZDV monotherapy, ZDV+LPV/r and ZDV+3TC+LPV/r, respectively. At delivery, 1%, 57% and 63% of women receiving ZDV monotherapy, ZDV+LPV/r or ZDV+3TC+LPV/r had a VL<50 copies/ml. The addition of 3TC to ZDV+LPV/r reduced the time to achieve a VL<50 copies/ml and the higher the pretreatment VL, the larger the effect 3TC had on reducing the time to VL<50 copies/ml. Conclusions: The addition of 3TC to ZDV+LPV/r was associated with a slight further VL reduction but the time to reach a VL<50 copies/ml was shorter. This beneicial effect of 3TC is crucial for prevention of motherto-child transmission in women who receive ARVs late and with high pretreatment VL.
format Journal
author Patumrat Sripan
Sophie Le Coeur
Lily Ingsrisawang
Tim R. Cressey
Naïm Bouazza
Frantz Foissac
Nicole Ngo-Giang-Huong
Patrinee Traisathit
Ussanee Srirompotong
Orada Patamasingh Na Ayudhaya
Achara Puangsombat
Jantana Jungpipun
Kanokwan Jittayanun
Jean Marc Tréluyer
Gonzague Jourdain
Marc Lallemant
Saïk Urien
author_facet Patumrat Sripan
Sophie Le Coeur
Lily Ingsrisawang
Tim R. Cressey
Naïm Bouazza
Frantz Foissac
Nicole Ngo-Giang-Huong
Patrinee Traisathit
Ussanee Srirompotong
Orada Patamasingh Na Ayudhaya
Achara Puangsombat
Jantana Jungpipun
Kanokwan Jittayanun
Jean Marc Tréluyer
Gonzague Jourdain
Marc Lallemant
Saïk Urien
author_sort Patumrat Sripan
title Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy
title_short Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy
title_full Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy
title_fullStr Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy
title_full_unstemmed Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy
title_sort contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on hiv viral load reduction during pregnancy
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84991493939&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/56248
_version_ 1681424656456744960